Trial · NCT01680159
Adverse events990
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 990
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Bronchitis | Infections and infestations | TA-650（Normal Dose Period）Overall | 0 | 46 | |
| other | Bronchitis | Infections and infestations | TA-650（Normal Dose Period）Plaque Psoriasis | 0 | 36 | |
| other | Bronchitis | Infections and infestations | TA-650（Normal Dose Period）Psoriatic Arthritis | 0 | 10 | |
| other | Bronchitis | Infections and infestations | TA-650（Dose Escalation Period）Overall | 1 | 51 | |
| other | Bronchitis | Infections and infestations | TA-650（Dose Escalation Period）Plaque Psoriasis | 1 | 31 | |
| other | Bronchitis | Infections and infestations | TA-650（Dose Escalation Period）Psoriatic Arthritis | 0 | 8 | |
| other | Bronchitis | Infections and infestations | TA-650（Dose Escalation Period）Pustular Psoriasis | 0 | 7 | |
| other | Bronchitis | Infections and infestations | TA-650（Dose Escalation Period）Psoriatic Erythroderma | 0 | 5 | |
| other | Bronchitis | Infections and infestations | TA-650（Entire Evaluation Period）Plaque Psoriasis | 1 | 36 | |
| other | Bronchitis | Infections and infestations | TA-650（Entire Evaluation Period）Psoriatic Arthritis | 0 | 10 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Normal Dose Period）Overall | 0 | 46 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Normal Dose Period）Plaque Psoriasis | 0 | 36 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Normal Dose Period）Psoriatic Arthritis | 0 | 10 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Dose Escalation Period）Overall | 1 | 51 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Dose Escalation Period）Plaque Psoriasis | 0 | 31 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Dose Escalation Period）Psoriatic Arthritis | 0 | 8 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Dose Escalation Period）Pustular Psoriasis | 0 | 7 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Dose Escalation Period）Psoriatic Erythroderma | 1 | 5 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Entire Evaluation Period）Plaque Psoriasis | 0 | 36 | |
| other | Conjunctivitis | Infections and infestations | TA-650（Entire Evaluation Period）Psoriatic Arthritis | 0 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01680159/events